Gene expression signature predicting high-grade prostate cancer responses to oxaliplatin

Molecular Pharmacology

Volumn 82, Issue 6, 2012, Pages 1205-1216

  Puyo, Stéphane ^a   Houed́é, Nadine ^a   Kauffmann, Audrey ^a   Richaud, Pierre ^a   Robert, Jacques ^a   Pourquier, Philippe ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; OXALIPLATIN;

ARTICLE; CELL STRAIN LNCAP; CHEMOSENSITIVITY; COMPUTER MODEL; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; MALE; NEOPLASM GRADING; ORGANOPLATINUM COMPOUNDS; PROSTATIC NEOPLASMS; TRANSCRIPTOME;

EID: 84869825826     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.080333     Document Type: Article

References (42)

1. Albertsen PC, Fryback DG, Storer BE, Kolon TF, and Fine J (1995) Long-term survival among men with conservatively treated localized prostate cancer. JAMA 274:626-631.
2. Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea MA, Duray PH, et al. (2005) Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 11:6823-6834. (Pubitemid 41428737)
3. Bonkhoff H and Berges R (2010) From pathogenesis to prevention of castration resistant prostate cancer. Prostate 70:100-112.
4. Bosetti C, Bertuccio P, Chatenoud L, Negri E, La Vecchia C, and Levi F (2011) Trends in mortality from urologic cancers in Europe, 1970-2008. Eur Urol 60:1-15.
5. Brooke GN and Bevan CL (2009) The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 10:18-25.
6. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, and Hemann MT (2008) Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA 105:9053-9058.
7. Carducci MA and Jimeno A (2006) Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 12:6296s-6300s. (Pubitemid 44703806)
8. Carroll AG, Voeller HJ, Sugars L, and Gelmann EP (1993) p53 oncogene mutations in three human prostate cancer cell lines. Prostate 23:123-134. (Pubitemid 23289894)
9. Clark JP and Cooper CS (2009) ETS gene fusions in prostate cancer. Nat Rev Urol 6:429-439.
10. Cunha GR and Matrisian LM (2002) It's not my fault, blame it on my microenvironment. Differentiation 70:469-472. (Pubitemid 36194312)
11. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS, et al. (2011) Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 12:245-255.
12. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005.
13. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, and Chinnaiyan AM (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412:822-826. (Pubitemid 32801464)
14. Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, Spicer B, Gurski C, Kantoff PW, and Smith MR (2009) Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 20:913-920.
15. Droz JP, Muracciole X, Mottet N, Ould Kaci M, Vannetzel JM, Albin N, Culine S, Rodier JM, Misset JL, Mackenzie S, et al. (2003) Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol 14:1291-1298. (Pubitemid 37039058)
16. Gasent Blesa JM, Giner Marco V, Giner-Bosch V, Cerezuela Fuentes P, and Alberola Candel V (2011) Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients. Am J Clin Oncol 34:155-159.
17. Gautier L, Cope L, Bolstad BM, and Irizarry RA (2004) affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20:307-315. (Pubitemid 38262761)
18. Gleason DF (1992) Histologic grading of prostate cancer: a perspective. Hum Pathol 23:273-279.
19. Hall MD, Handley MD, and Gottesman MM (2009) Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci 30:546-556.
20. 6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell Mol Life Sci 67:3663-3681.
21. Kauffmann A and Huber W (2010) Microarray data quality control improves the detection of differentially expressed genes. Genomics 95:138-142.
22. Kauffmann A, Rayner TF, Parkinson H, Kapushesky M, Lukk M, Brazma A, and Huber W (2009) Importing ArrayExpress datasets into R/Bioconductor. Bioinformatics 25:2092-2094.
23. Kim MK, Osada T, Barry WT, Yang XY, Freedman JA, Tsamis KA, Datto M, Clary BM, Clay T, Morse MA, et al. (2012) Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer. Mol Cancer Ther 11:1500-1509.
24. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, et al. (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101:811-816. (Pubitemid 38121040)
25. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, Grimshaw A, and Theodorescu D (2007) A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA 104:13086-13091. (Pubitemid 351737597)
26. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, and Isaacs WB (2001) Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 61:4683-4688. (Pubitemid 32691876)
27. Luo J, Dunn T, Ewing C, Sauvageot J, Chen Y, Trent J, and Isaacs W (2002) Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate 51:189-200. (Pubitemid 34492640)
28. Mancuso A, Oudard S, and Sternberg CN (2007) Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. Crit Rev Oncol Hematol 61:176-185. (Pubitemid 46091748)
29. Mike S, Harrison C, Coles B, Staffurth J, Wilt TJ, and Mason MD (2006) Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev CD005247.
30. Paller CJ and Antonarakis ES (2011) Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther 5:117-124.
31. Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, Stark JR, Fiorentino M, Perner S, Finn S, et al. (2011) mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol 29:2391-2396.
32. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236-244. (Pubitemid 30132190)
33. Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813-823.
34. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, et al. (2002) Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1:203-209. (Pubitemid 41039166)
35. Smyth GK (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:Article 3.
36. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, et al. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457:910-914.
37. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA, and Kattan MW (2005) Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 23:7005-7012.
38. True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, Beer TM, Gelmann E, Datta M, Mostaghel E, et al. (2006) A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 103:10991-10996. (Pubitemid 44148406)
39. Vekris A, Meynard D, Haaz MC, Bayssas M, Bonnet J, and Robert J (2004) Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res 64:356-362. (Pubitemid 38114118)
40. Wang L, Tang H, Thayanithy V, Subramanian S, Oberg AL, Cunningham JM, Cerhan JR, Steer CJ, and Thibodeau SN (2009) Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 69:9490-9497.
41. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Konishi T, Horie H, Ikeuchi H, et al. (2011) Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. Clin Transl Oncol 13:419-425.
42. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF Jr, and Hampton GM (2001) Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61:5974-5978. (Pubitemid 32762523)